Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis Nat Rev Dis Primers. 2019;5(1):56. https://doi.org/10.1038/s41572-019-0106-z.

Article  PubMed  Google Scholar 

Martin SS, Aday AW, Allen NB, Almarzooq ZI, Anderson CAM, Arora P, et al. Circulation. 2025;151(8):e41–660. https://doi.org/10.1161/cir.0000000000001303. 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–47. https://doi.org/10.1097/hep.0000000000000004.

Article  PubMed  PubMed Central  Google Scholar 

Zhang X, Linden S, Levesley CR, He X, Yang Z, Barnet SD, et al. Projected Trends in Metabolic Dysfunction-Associated Steatotic Liver Disease Mortality Through 2040. JAMA Netw Open. 2025;8(6):e2516367. https://doi.org/10.1001/jamanetworkopen.2025.16367.

Article  PubMed  PubMed Central  Google Scholar 

Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691–702. https://doi.org/10.1136/gutjnl-2023-330595.

Article  CAS  PubMed  Google Scholar 

Das S, Anand SK, McKinney MP, Richard KSE, Mahmud I, Rohilla S, et al. Sex-based multiomics analysis uncovers metabolic and molecular mediators linking MASH and atherosclerosis. JHEP Rep. 2025;101703. https://doi.org/10.1016/j.jhepr.2025.101703.

Finney AC, Das S, Kumar D, McKinney MP, Cai B, Yurdagul A Jr., et al. The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease. Front Cardiovasc Med. 2023;10:1116861. https://doi.org/10.3389/fcvm.2023.1116861.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835. https://doi.org/10.1097/hep.0000000000000323.

Article  PubMed  PubMed Central  Google Scholar 

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–22. https://doi.org/10.1038/s41591-018-0104-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iturbe-Rey S, Maccali C, Arrese M, Aspichueta P, Oliveira CP, Castro RE, et al. Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD). Atherosclerosis. 2025;400:119053. https://doi.org/10.1016/j.atherosclerosis.2024.119053.

Article  CAS  PubMed  Google Scholar 

Dai Q, Ain Q, Seth N, Rooney M, Zipprich A. Liver sinusoidal endothelial cells: Friend or foe in metabolic dysfunction- associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis. Dig Liver Dis. 2025;57(5):493–503. https://doi.org/10.1016/j.dld.2025.01.189.

Article  CAS  PubMed  Google Scholar 

Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol. 2022;22(7):429–43. https://doi.org/10.1038/s41577-021-00639-3.

Article  CAS  PubMed  Google Scholar 

Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397–411. https://doi.org/10.1038/nrgastro.2017.38.

Article  CAS  PubMed  Google Scholar 

Koh JH, Ng CH, Nah B, Tan DJH, Loomba R, Huang DQ. NASH is the Leading Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol. 2024;22(1):197–e93. https://doi.org/10.1016/j.cgh.2023.05.019.

Article  PubMed  Google Scholar 

Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145(3):341–55. https://doi.org/10.1016/j.cell.2011.04.005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009;27:165–97. https://doi.org/10.1146/annurev.immunol.021908.132620.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stroope C, Nettersheim FS, Coon B, Finney AC, Schwartz MA, Ley K, et al. Dysregulated cellular metabolism in atherosclerosis: mediators and therapeutic opportunities. Nat Metab. 2024;6(4):617–38. https://doi.org/10.1038/s42255-024-01015-w.

Article  PubMed  PubMed Central  Google Scholar 

Hetherington I, Totary-Jain H. Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations. Mol Ther. 2022;30(10):3106–17. https://doi.org/10.1016/j.ymthe.2022.08.024.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim HY, Rinella ME. Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment. Clin Mol Hepatol. 2025;31(3):753–70. https://doi.org/10.3350/cmh.2025.0083.

Article  PubMed  PubMed Central  Google Scholar 

Steen DL, Khan I, Andrade K, Koumas A, Giugliano RP. Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239 234 Patients During 2005 to 2018 in the United States. J Am Heart Assoc. 2022;11(9):e022198. https://doi.org/10.1161/jaha.121.022198.

Article  PubMed  PubMed Central  Google Scholar 

Song P, Fang Z, Wang H, Cai Y, Rahimi K, Zhu Y, et al. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. Lancet Glob Health. 2020;8(5):e721–9. https://doi.org/10.1016/s2214-109x(20)30117-0.

Article  PubMed  Google Scholar 

Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology. 2007;132(6):2191–207. https://doi.org/10.1053/j.gastro.2007.03.055.

Article  CAS  PubMed  Google Scholar 

Rom O, Grajeda-Iglesias C, Najjar M, Abu-Saleh N, Volkova N, Dar DE, et al. Atherogenicity of amino acids in the lipid-laden macrophage model system in vitro and in atherosclerotic mice: a key role for triglyceride metabolism. J Nutr Biochem. 2017;45:24–38. https://doi.org/10.1016/j.jnutbio.2017.02.023.

Article  CAS  PubMed  Google Scholar 

Gaggini M, Carli F, Rosso C, Buzzigoli E, Marietti M, Della Latta V, et al. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. Hepatology. 2018;67(1):145–58. https://doi.org/10.1002/hep.29465.

Article  CAS  PubMed  Google Scholar 

Nitz K, Lacy M, Atzler D. Amino Acids and Their Metabolism in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2019;39(3):319–30. https://doi.org/10.1161/atvbaha.118.311572.

Article  CAS  PubMed  Google Scholar 

Rom O, Liu Y, Liu Z, Zhao Y, Wu J, Ghrayeb A, et al. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Sci Transl Med. 2020;12(572). https://doi.org/10.1126/scitranslmed.aaz2841.

Rom O, Liu Y, Finney AC, Ghrayeb A, Zhao Y, Shukha Y, et al. Induction of glutathione biosynthesis by glycine-based treatment mitigates atherosclerosis. Redox Biol. 2022;52:102313. https://doi.org/10.1016/j.redox.2022.102313.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghrayeb A, Finney AC, Agranovich B, Peled D, Anand SK, McKinney MP, et al. Serine synthesis via reversed SHMT2 activity drives glycine depletion and acetaminophen hepatotoxicity in MASLD. Cell Metab. 2024;36(1):116–e297. https://doi.org/10.1016/j.cmet.2023.12.013.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Das S, Finney AC, Anand SK, Rohilla S, Liu Y, Pandey N, et al. Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis. Nat Metab. 2024;6(10):1939–62. https://doi.org/10.1038/s42255-024-01134-4.

Article  CAS  PubMed